Fig. 3 | Scientific Reports

Fig. 3

From: Temporal correlations between RBD-ACE2 blocking and binding antibodies to SARS-CoV-2 variants in CoronaVac-vaccinated individuals and their persistence in COVID-19 patients

Fig. 3

RBD-ACE2 blocking antibody (A), anti-spike antibody (B), and anti-RBD IgG antibody levels (C) in COVID-19 patients. Blocking antibodies against ancestral SARS-CoV-2 and 12 non-Omicron and Omicron variants were detected by multiplex sVNT, anti-spike antibodies were detected by the Elecsys® anti-spike assay, and anti-RBD IgG antibodies against SARS-CoV-2 RBD of the Delta variant were detected by ELISA. A negative result for nAbs was defined as a percent inhibition lower than 30% (indicated by the dotted red line), whereas a negative result for anti-spike antibodies was defined levels lower than 0.8 U/ml. The Kruksall-Wallis test with Dunn’s multiple comparison test was used to assess differences between the groups. Data of nAb and anti-RBD IgG levels were obtained from30,35.

Back to article page